Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients.
Axonal conduction and injury in multiple sclerosis: the role of sodium channels.
Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA
BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
Roche's new time-saving subcutaneous formulation of MabThera approved in Europe for the treatment of common forms of non-Hodgkin Lymphoma
Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
It is better to be in a clinical trial than not: lessons learnt from clinical neurology--the management of acute multiple sclerosis relapses.
Poor sleep in patients with multiple sclerosis.
Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies.
The Brief Repeatable Battery: psychometrics and normative values with age, education and gender corrections in a Serbian population.
Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy.
Motor skill learning requires active central myelination.
Novartis gains approval for Gilenya® as a first-line disease modifying oral therapy for multiple sclerosis in Switzerland and Australia
Sex-related factors in multiple sclerosis susceptibility and progression.
Demyelination affects temporal aspects of perception: An optic neuritis study.
[Plasmapheresis in central nervous system disorders].
Food and Drug Administration Approval Letter for Alemtuzumab
Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo - therapeutic potential for peripheral neuropathies: results of a randomised controlled trial.
Cyclophosphamide
Apitope Announces Positive Results from Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis
Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally.
Stress Management and Multiple Sclerosis: A Randomized Controlled Trial.
4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis.
Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis.
Cross-cultural Adaptation, Reliability, and Validity of the BICAMS in Brazil.

Pages